We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

LAMP Assay Developed for Trichomoniasis

By LabMedica International staff writers
Posted on 26 Aug 2014
Print article
Image: Scanning electron micrograph of a Trichomonas vaginalis trophozoite (Photo courtesy of Dr. Dennis Kunkel).
Image: Scanning electron micrograph of a Trichomonas vaginalis trophozoite (Photo courtesy of Dr. Dennis Kunkel).
A loop-mediated isothermal amplification (LAMP) assay targeting a repeated DNA species-specific sequence was developed for detection of Trichomonas vaginalis, the causative agent of trichomoniasis.

The most common laboratory diagnostic tests for T. vaginalis infections include wet-mount microscopy; culture; and, recently, nucleic acid amplification tests (NAATs) using genital swab, urine, or semen samples. Culture is the gold standard for diagnosis of T. vaginalis, although its sensitivity can be as low as microscopy, and requires at least a week of incubation and daily microscopy for optimal performance.

Parasitologists at the University of the Philippines (Manila, Philippines) collected a total of 16 genital swabs and two urine specimens were from women attending a Reproductive Health and Wellness Center. Mid-log-phase axenic T. vaginalis cultures (107 trichomonads/mL) and 1 mL aliquot of clinical specimens were pelleted by centrifugation. All specimens were examined for the presence of T. vaginalis by polymerase chain reaction (PCR).

LAMP primers specific for T. vaginalis were designed based on the highly repeated two kilo-base pair (2-Kbp) DNA fragment of T. vaginalis. The LAMP products were assessed by gel electrophoresis, assessment of turbidity, and addition of SYBR Safe DNA Gel Stain (Invitrogen, Carlsbad, CA, USA) and visualized under an ultra-violet UV transilluminator (UVP; Upland, CA, USA). An orange-to-pink color change under natural light or a dull to fluorescent signal under UV transilluminator indicated a positive reaction.

Of the 16 genital swab specimens, 15 were negative by PCR, and the two urine specimens were also negative. All negative samples were pooled and used for spiking in the analytical sensitivity evaluation. In spiked genital swab samples, the results indicate that the detection limit of the LAMP method was 100 trichomonads/mL or one trichomonad either by gel electrophoresis, turbidity, or addition of SYBR Safe, while the detection limit of PCR was 103 trichomonads/mL or 1,000 trichomonads. The T. vaginalis LAMP exhibited no cross-reactivity with DNA extracts from closely-related trichomonads, Trichomonas tenax and Pentatrichomonas hominis, and other enteric and urogenital microorganisms, Entamoeba histolytica, Candida albicans, Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus.

The authors concluded that the T. vaginalis LAMP assay developed was simple, rapid, sensitive, and specific method for the detection of trichomoniasis, the most common curable sexually transmitted infection. This efficient and cost-effective NAAT has a great potential application for accurate diagnosis and large-scale surveillance, screening, and control of trichomoniasis in point-of-care and resource-limited settings. The study was published in the July 2014 issue of the journal Diagnostic Microbiology and Infectious Disease.

Related Links:

University of the Philippines
Invitrogen
UVP


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory QC Panel
Assayed Respiratory Control Panel
New
Bordetella Pertussis Molecular Assay
Alethia Pertussis

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.